Table 2.
Correlation between total plasma cfDNA level and clinical characteristics.
| Variables | Before chemotherapy | After chemotherapy |
|---|---|---|
| Gender | ||
| Male | 35.47 ± 5.39 | 17.83 ± 2.28 |
| Female | 36.26 ± 4.36 | 18.35 ± 1.98 |
| P | 0.3901 | 0.1928 |
| Age | ||
| >65 | 36.84 ± 5.42 | 18.09 ± 2.10 |
| ≤65 | 35.49 ± 4.71 | 17.86 ± 2.27 |
| P | 0.1781 | 0.6106 |
| Tumor site | ||
| Colon | 35.79 ± 4.92 | 18.16 ± 2.21 |
| Rectum | 35.39 ± 4.43 | 17.70 ± 2.12 |
| P | 0.6426 | 0.2487 |
| TNM stage | ||
| II/III | 36.03 ± 4.19 | 17.99 ± 2.13 |
| IV | 35.71 ± 5.97 | 18.25 ± 2.39 |
| P | 0.7306 | 0.5331 |
| Tumor differentiation | ||
| Low-medium | 35.48 ± 3.87 | 18.75 ± 1.90 |
| High | 33.16 ± 4.05 | 16.89 ± 2.02 |
| P | 0.0049 | <0.0001 |
| CA125 | ||
| ≥35 U/ml | 37.16 ± 3.92 | 18.73 ± 1.97 |
| <35 U/ml | 34.62 ± 4.99 | 17.40 ± 2.08 |
| P | 0.0048 | 0.0009 |
| CEA | ||
| ≥3.5 ng/mL | 37.90 ± 5.09 | 18.90 ± 2.12 |
| <3.5 ng/mL | 35.52 ± 4.35 | 17.52 ± 2.03 |
| P | 0.0128 | 0.0006 |
| NSE | ||
| ≥16.3 ng/mL | 36.70 ± 3.87 | 18.58 ± 2.33 |
| <16.3 ng/mL | 35.90 ± 5.14 | 18.25 ± 2.34 |
| P | 0.6494 | 0.6847 |
| AFP | ||
| ≥7 ng/mL | 34.72 ± 4.75 | 18.08 ± 2.25 |
| <7 ng/mL | 36.02 ± 5.08 | 17.57 ± 0.94 |
| P | 0.5756 | 0.2725 |
| E-cadherin | ||
| High expression | 35.38 ± 4.84 | 17.72 ± 2.28 |
| Low expression | 35.42 ± 5.32 | 18.32 ± 2.21 |
| P | 0.9645 | 0.1504 |
| VEGF | ||
| High expression | 37.09 ± 4.50 | 19.95 ± 1.83 |
| Low expression | 35.41 ± 4.32 | 18.43 ± 2.06 |
| P | 0.0468 | <0.0001 |
| mTor | ||
| High expression | 35.82 ± 4.85 | 18.12 ± 1.65 |
| Low expression | 35.80 ± 4.49 | 18.45 ± 2.24 |
| P | 0.9832 | 0.4822 |
| MMP-9 | ||
| High expression | 36.60 ± 4.87 | 17.83 ± 2.04 |
| Low expression | 35.17 ± 5.01 | 18.13 ± 1.99 |
| P | 0.1232 | 0.4289 |
Bold values mean P < 0.01.